Project Grant HT94252410067

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to validate a novel preclinical mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test prevention agents. The $602,315 award to the University of Colorado-Denver will: Define the human relevance of the in vivo NTCU/cigarette smoke mouse model of lung SCC premalignant lesions. Validate an ex vivo precision cut lung slice...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...

This federal Project Grant award of $216,972 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to understand and target vulnerabilities governing the G1/S transition and replication stress in small cell lung cancer (SCLC). The key objectives are to: 1) determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA levels and R-loops, and develop therapeutic approaches targeting...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...

This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...

This $548,915 five-year Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) supports research to elucidate a novel tumor suppressive axis involving the stress activated protein kinase (SAPK) pathway in small cell lung cancer (SCLC). The research aims to leverage cellular models, genetically engineered mouse models, and human tumor datasets to define the biological roles of the SAPK/AP-1 pathway in SCLC tumor suppression. Key objectives...

The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...

This $703,410 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University (NYU) School of Medicine to investigate molecular mechanisms underlying the transition from lung adenocarcinoma to squamous cell carcinoma, which can contribute to resistance to KRAS inhibitor therapies. The research aims to identify chromatin regulators that drive this lineage transition, and systematically decouple the...

This Project Grant award of $230,010 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to unravel the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The award was granted to the University of Chicago and will run from March 1, 2025 to February 28, 2027. The research integrates human pluripotent stem cell-derived SCLC models, clinical samples, and patient-derived...

The National Cancer Institute (NCI) awarded a $136,266 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The grant supports research to determine mechanisms by which inactivating the EED protein can block the transformation of lung adenocarcinoma (LUAD) into small cell lung cancer (SCLC), a common resistance mechanism to EGFR inhibitor therapies. The research aims to 1) understand how EED inactivation promotes...